2018 APCaRI Fall Symposium – Knowledge, Action, Impact
On October 26 – 27, 2018 APCaRI will celebrate its 11th research meeting at the Banff Park Lodge, in Banff, Alberta. Previous fall symposia have had over 60 participants participating in this fun and enriching event, including clinicians, scientists, clinical research personnel, trainees, benefactors and representatives of PCa support groups. Plan on attending the 2018 Fall symposium to discuss and share ideas and enjoy the beautiful Rockies!
Please submit your abstracts to Rume at firstname.lastname@example.org. Please let Rume know as soon as possible if you cannot attend. The APCaRI Fall symposium is generously supported by the Alberta Cancer Foundation and its’ donors
Dates to remember:
Trainee abstract submission deadline is September 10
Registration deadline is September 14
Submit abstracts to email@example.com.
To stay up to date on all the latest news and publications, subscribe to our newsletter!
Konstantin Stoletov and Lian Willetts co-first-authored an article published recently in Nature Communications titled “Quantitative in vivo whole genome motility screen reveals novel therapeutic targets to block cancer metastasis“. These two researchers, along with fellow Lewis lab members and collaborators from the University of Calgary and Vanderbilt University set out to determine what genes and signaling networks are involved in the rate-limiting steps of solid tumour cell motility, in vivo. But the team was hampered by the lack of an effective, quantitative, in vivo imaging platform. They wanted to visualize the movement of tumour cells, or lack of, in real-time AND use this intravital imaging platform to screen a large bank of tumour cells harboring single gene mutations for cells that show a loss of motility.
When tumour cells metastasize they get into (intravasate) the hosts’ bloodstream and use the vascular system like roadways to travel throughout the body. This lets the tumour cells colonize new microenvironments where they will proliferate and form new tumours. So metastatis is really dependent on tumour cell motility. Although there are many different types of solid tumours known, previous research suggests that if the tumour cells can mobilize and metastasize then the expressed motility-related genes share homology across tumour types. This is great news because it would mean that therapeutic targets aimed at stopping motility could also stop metastasis for many tumour types!
The Lewis lab researchers and their collaborators developed an in vivo, fluorescent, time-lapse screening platform that uses shell-less avian embryos for tumour growth and formation. The avian embryo is an excellent tumour model because the tumour cells will grow on the chorioallantoic membrane in a single cell layer, making in vivo cell motility imaging actually doable.
Using this platform the team screened over 30 000 human genes for the ones needed for cell motility and ultimately found 17 genes that looked to be effective metastasis-blocking gene targets. Stoletov, along with other Lewis lab members, are continuing this research by studying these 17 attractive candidates further to determine which one (s) would make therapeutic metastasis-blocking targets.
This article has generated a lot of interest in the scientific community and in the general public! Check out the links below to mentions and articles in the media.